NexGard

Country: European Union

Language: Danish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

afoxolaner

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QP53BE01

INN (International Name):

afoxolaner

Therapeutic group:

Hunde

Therapeutic area:

Isoxazolines, Ectoparasiticides til systemisk brug

Therapeutic indications:

Behandling af loppeangreb på hunde (Ctenocephalides felis og C. canis) i mindst 5 uger. Produktet kan bruges som en del af en behandlingsstrategi til bekæmpelse af loppe allergi dermatitis (FAD). Behandling af kryds angreb i hunde (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus). En behandling, der dræber flåter i op til en måned. Lopper og flåter skal vedhæfte til værten og påbegynde fodring for at blive udsat for det aktive stof. Behandling af demodicosis (forårsaget af Demodex canis). Behandling af sarcoptic mange (forårsaget af Sarcoptes scabiei var. canis).

Product summary:

Revision: 11

Authorization status:

autoriseret

Authorization date:

2014-02-11

Patient Information leaflet

                                15
B. INDLÆGSSEDDEL
16
INDLÆGSSEDDEL:
NEXGARD 11 MG TYGGETABLETTER TIL HUND 2–4
KG
NEXGARD 28 MG TYGGETABLETTER TIL HUND >4–10
KG
NEXGARD 68 MG TYGGETABLETTER TIL HUND >10–25
KG
NEXGARD 136 MG TYGGETABLETTER TIL HUND >25–50
KG
1.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN
SAMT PÅ DEN INDEHAVER AF VIRKSOMHEDSGODKENDELSE, SOM ER
ANSVARLIG FOR BATCHFRIGIVELSE, HVIS FORSKELLIG HERFRA
Indehaver af markedsføringstilladelsen:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
TYSKLAND
Fremstiller ansvarlig for batchfrigivelse:
Boehringer Ingelheim Animal Health France SCS
4 Chemin du Calquet
31000 Toulouse
Frankrig
2.
VETERINÆRLÆGEMIDLETS NAVN
NexGard 11 mg tyggetabletter til hund 2–4 kg
NexGard 28 mg tyggetabletter til hund >4–10 kg
NexGard 68 mg tyggetabletter til hund >10–25 kg
NexGard 136 mg tyggetabletter til hund >25–50 kg
afoxolaner
3.
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER
En tyggetablet indeholder:
NexGard
Afoxolaner (mg)
Tyggetabletter til hund 2–4 kg
11,3
Tyggetabletter til hund >4–10 kg
28,3
Tyggetabletter til hund >10–25 kg
68
Tyggetabletter til hund >25–50 kg
136
Marmoreret rød til rødbrun, rund (tablet til hund 2–4 kg) eller
rektangulær (tablet til hund >4–10 kg,
tablet til hund >10–25 kg og tablet til hund >25–50 kg).
4.
INDIKATIONER
Behandling af loppeangreb hos hund (
_Ctenocephalides felis_
og
_C.Canis_
) i mindst 5 uger. Præparatet
kan indgå som led i behandlingen af loppeallergi (FAD).
Behandling af flåtangreb hos hund (
_Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, _
_Rhipicephalus sanguineus_
). En behandling dræber flåter i op til én måned.
Lopper og flåter skal bide sig fast på værtsdyret og starte indtag
af føde for at blive udsat for det aktive
stof.
Behandling af infektion med
_Demodex canis_
(”hårsækmider”).
_ _
17
Behandling af skab (forårsaget af
_Sarcoptes scabiei _
var.
_canis_
)
5.
KONTRAINDIKATIONER
Bør ikke anvendes i tilfælde af overfølsomhed over for det aktive
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
BILAG I
PRODUKTRESUME
2
1.
VETERINÆRLÆGEMIDLETS NAVN
NexGard 11 mg tyggetabletter til hund 2–4 kg
NexGard 28 mg tyggetabletter til hund >4–10 kg
NexGard 68 mg tyggetabletter til hund >10–25 kg
NexGard 136 mg tyggetabletter til hund >25–50 kg
2.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING
En tyggetablet indeholder:
AKTIVT STOF:
NexGard
Afoxolaner (mg)
Tyggetabletter til hund 2–4 kg
11,3
Tyggetabletter til hund >4–10 kg
28,3
Tyggetabletter til hund >10–25 kg
68
Tyggetabletter til hund >25–50 kg
136
Alle hjælpestoffer er anført under pkt. 6.1
3.
LÆGEMIDDELFORM
Tyggetablet.
Marmoreret rød til rødbrun, rund (tablet til hund 2–4 kg) eller
rektangulær (tablet til hund >4–10 kg,
tablet til hund >10–25 kg og tablet til hund >25–50 kg).
4.
KLINISKE OPLYSNINGER
4.1
DYREARTER, SOM LÆGEMIDLET ER BEREGNET TIL
Hund.
4.2
TERAPEUTISKE INDIKATIONER MED ANGIVELSE AF DYREARTER, SOM LÆGEMIDLET
ER BEREGNET TIL
Behandling af loppeinfestation hos hund (
_Ctenocephalides felis_
og
_C.Canis_
) i mindst 5 uger.
Præparatet kan indgå som led i behandlingen af loppebetinget
allergisk dermatitis (FAD).
Behandling af flåtinfestation hos hund (
_Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, _
_Rhipicephalus sanguineus_
). En behandling dræber flåter i op til en måned.
Lopper og flåter skal bide sig fast på værtsdyret og starte indtag
af føde for at blive eksponeret for det
aktive stof.
Behandling af demodecose (forårsaget af
_Demodex canis_
).
Behandling af skab (forårsaget af
_Sarcoptes scabiei _
var.
_canis_
)
4.3
KONTRAINDIKATIONER
Bør ikke anvendes i tilfælde af overfølsomhed over for det aktive
stof eller over for et eller flere af
hjælpestofferne.
3
4.4
SÆRLIGE ADVARSLER FOR HVER ENKELT DYREART, SOM LÆGEMIDLET ER
BEREGNET TIL
Parasitter skal have startet indtag af føde fra værtsdyret for at
blive eksponeret for afoxolaner; derfor
kan risikoen for overførsel af parasitbårne lidelser ikke udelukkes.
4.5
SÆRLIGE FORSIGTIGHEDSREGLER VEDRØRENDE BRUGEN
Særlige forsigtighedsre
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-04-2020
Public Assessment Report Public Assessment Report Bulgarian 10-12-2018
Patient Information leaflet Patient Information leaflet Spanish 08-04-2020
Public Assessment Report Public Assessment Report Spanish 10-12-2018
Patient Information leaflet Patient Information leaflet Czech 08-04-2020
Public Assessment Report Public Assessment Report Czech 10-12-2018
Patient Information leaflet Patient Information leaflet German 08-04-2020
Public Assessment Report Public Assessment Report German 10-12-2018
Patient Information leaflet Patient Information leaflet Estonian 08-04-2020
Public Assessment Report Public Assessment Report Estonian 10-12-2018
Patient Information leaflet Patient Information leaflet Greek 08-04-2020
Public Assessment Report Public Assessment Report Greek 10-12-2018
Patient Information leaflet Patient Information leaflet English 08-04-2020
Public Assessment Report Public Assessment Report English 10-12-2018
Patient Information leaflet Patient Information leaflet French 08-04-2020
Public Assessment Report Public Assessment Report French 10-12-2018
Patient Information leaflet Patient Information leaflet Italian 08-04-2020
Public Assessment Report Public Assessment Report Italian 10-12-2018
Patient Information leaflet Patient Information leaflet Latvian 08-04-2020
Public Assessment Report Public Assessment Report Latvian 10-12-2018
Patient Information leaflet Patient Information leaflet Lithuanian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-04-2020
Public Assessment Report Public Assessment Report Lithuanian 10-12-2018
Patient Information leaflet Patient Information leaflet Hungarian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 08-04-2020
Public Assessment Report Public Assessment Report Hungarian 10-12-2018
Patient Information leaflet Patient Information leaflet Maltese 08-04-2020
Public Assessment Report Public Assessment Report Maltese 10-12-2018
Patient Information leaflet Patient Information leaflet Dutch 08-04-2020
Public Assessment Report Public Assessment Report Dutch 10-12-2018
Patient Information leaflet Patient Information leaflet Polish 08-04-2020
Public Assessment Report Public Assessment Report Polish 10-12-2018
Patient Information leaflet Patient Information leaflet Portuguese 08-04-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 08-04-2020
Public Assessment Report Public Assessment Report Portuguese 10-12-2018
Patient Information leaflet Patient Information leaflet Romanian 08-04-2020
Public Assessment Report Public Assessment Report Romanian 10-12-2018
Patient Information leaflet Patient Information leaflet Slovak 08-04-2020
Public Assessment Report Public Assessment Report Slovak 10-12-2018
Patient Information leaflet Patient Information leaflet Slovenian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 08-04-2020
Public Assessment Report Public Assessment Report Slovenian 10-12-2018
Patient Information leaflet Patient Information leaflet Finnish 08-04-2020
Public Assessment Report Public Assessment Report Finnish 10-12-2018
Patient Information leaflet Patient Information leaflet Swedish 08-04-2020
Public Assessment Report Public Assessment Report Swedish 10-12-2018
Patient Information leaflet Patient Information leaflet Norwegian 08-04-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 08-04-2020
Patient Information leaflet Patient Information leaflet Icelandic 08-04-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 08-04-2020
Patient Information leaflet Patient Information leaflet Croatian 08-04-2020
Public Assessment Report Public Assessment Report Croatian 10-12-2018

Search alerts related to this product

View documents history